Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer DOI
S. Li, Yuansheng Liu, Xiaojun Sui

et al.

Nanomedicine, Journal Year: 2024, Volume and Issue: 19(24), P. 1977 - 1993

Published: Sept. 3, 2024

Aim: To evaluate the anti-pancreatic cancer effect of novel Tubeimoside I multifunctional liposomes combined with gemcitabine.

Language: Английский

ROS: A “booster” for chronic inflammation and tumor metastasis DOI

Anqi Chen,

Haifeng Huang,

S. S. Fang

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: 1879(6), P. 189175 - 189175

Published: Aug. 31, 2024

Language: Английский

Citations

19
Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment DOI Open Access
Nikolaos Vitorakis, Antonios N. Gargalionis, Kostas A. Papavassiliou

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(16), P. 2876 - 2876

Published: Aug. 19, 2024

Pancreatic cancer demonstrates an ever-increasing incidence over the last years and represents one of top causes cancer-associated mortality. Cells tumor microenvironment (TME) interact with cells in pancreatic ductal adenocarcinoma (PDAC) tumors to preserve cells' metabolism, inhibit drug delivery, enhance immune suppression mechanisms finally develop resistance chemotherapy immunotherapy. New strategies target TME genetic alterations specific pathways cell populations TME. Complex molecular interactions between PDAC including fibroblasts, myeloid-derived suppressor cells, stellate tumor-associated macrophages, neutrophils, regulatory T cells. In present review, we aim fully explore landscape discuss current targeting provide thoughts for further research preclinical testing.

Language: Английский

Citations

4
Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer DOI

Yumeng Hu,

Yifu Hu,

Shaobo Zhang

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: 614, P. 217523 - 217523

Published: Feb. 6, 2025

Language: Английский

Citations

0
SJB2-043, a USP1 Inhibitor, Suppresses A549 Cell Proliferation, Migration, and EMT via Modulation of PI3K/AKT/mTOR, MAPK, and Wnt Signaling Pathways DOI Creative Commons
Li Wu,

Meng Yu,

Hongge Liang

et al.

Current Issues in Molecular Biology, Journal Year: 2025, Volume and Issue: 47(3), P. 155 - 155

Published: Feb. 27, 2025

Objective: Non-small cell lung cancer (NSCLC) remains one of the most significant contributors to cancer-related mortality. This investigation explores influence and underlying mechanisms USP1 inhibitor SJB2-043 on A549 cells, with aim advancing development anti-NSCLC therapeutics. Methods: Publicly available databases were utilized assess expression its association progression NSCLC. Gene variations ascertained through RNA sequencing, followed by Kyoto Encyclopedia Genes Genomes Ontology pathway enrichment evaluations. Various doses administered cells evaluate impact multiplication, motility, apoptosis, cycle using CCK-8 assays, colony formation, wound healing, flow cytometry, Western blotting (WB). Results: was found be overexpressed in NSCLC specimens linked adverse prognosis. Treatment markedly inhibited proliferation migration, diminished clonogenic potential, triggered apoptosis a dose-dependent manner. Modifications observed, showing an elevated percentage G2 phase while exhibiting parallel decline G1 phase. WB examination demonstrated protein levels N-cadherin, CyclinB1, CDK1, C-myc, Bcl-2, p-ERK/ERK, p-p38/p38, p-JNK/JNK, p-AKT/AKT, p-mTOR/mTOR, alongside upregulation E-cadherin, ZO-1, occludin, p53, Bax, p-β-catenin/β-catenin, GSK3β. Conclusions: exerts suppressive effect proliferation, epithelial–mesenchymal transition enhancing apoptosis. These cellular effects appear mediated inhibition MAPK, Wnt/β-catenin, PI3K/AKT/mTOR signaling cascades, addition modulation cycle.

Language: Английский

Citations

0
SIK1 promotes ferroptosis resistance in pancreatic cancer via HDAC5-STAT6-SLC7A11 axis DOI
Hao Zhang, Tao Ma,

Xiaofeng Wen

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217726 - 217726

Published: April 1, 2025

Language: Английский

Citations

0
Enhanced cytokine signaling and ferroptosis defense interplay initiates obesity-associated pancreatic ductal adenocarcinoma DOI

Rexiati Ruze,

Cheng Yuan,

Jianlu Song

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 601, P. 217162 - 217162

Published: Aug. 9, 2024

Language: Английский

Citations

3
Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer DOI
S. Li, Yuansheng Liu, Xiaojun Sui

et al.

Nanomedicine, Journal Year: 2024, Volume and Issue: 19(24), P. 1977 - 1993

Published: Sept. 3, 2024

Aim: To evaluate the anti-pancreatic cancer effect of novel Tubeimoside I multifunctional liposomes combined with gemcitabine.

Language: Английский

Citations

1